- Carl Zeiss Meditec reported revenue of EU947.2 million in the first half of the year.
- The revenue from ophthalmic devices stood at EU700.6 million.
- Microsurgery contributed EU246.5 million to the total revenue.
- The company expects its growth to accelerate again in the second half of the fiscal year 2023/24.
- This acceleration in growth is attributed to the cost-control measures taken by the company.
- The recovery in operating results due to cost-control should help the company reach its annual targets.
- Analysts’ ratings on the company’s stock stand at 7 buys, 9 holds, and 4 sells.
A look at Carl Zeiss Meditec Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Carl Zeiss Meditec AG, a company specializing in medical technology for ophthalmology, has received encouraging Smart Scores across various key factors. With a strong Growth score of 4 and Momentum score of 5, the company seems to be on a positive trajectory for the long term. This indicates a promising outlook for potential expansion and market performance.
In addition, Carl Zeiss Meditec also scores reasonably well on Resilience with a score of 3, showing a level of stability in the face of market challenges. While the Value and Dividend scores are a bit lower at 2 each, suggesting some room for improvement in these areas, the overall outlook for the company appears optimistic based on the Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
